ATE265208T1 - Verwendung von allosterischen hämoglobinmodifikatoren zur verringerung der sauerstoffaffinität im blut - Google Patents

Verwendung von allosterischen hämoglobinmodifikatoren zur verringerung der sauerstoffaffinität im blut

Info

Publication number
ATE265208T1
ATE265208T1 AT92912561T AT92912561T ATE265208T1 AT E265208 T1 ATE265208 T1 AT E265208T1 AT 92912561 T AT92912561 T AT 92912561T AT 92912561 T AT92912561 T AT 92912561T AT E265208 T1 ATE265208 T1 AT E265208T1
Authority
AT
Austria
Prior art keywords
blood
oxygen affinity
reduce oxygen
allosteric hemoglobin
compound
Prior art date
Application number
AT92912561T
Other languages
English (en)
Inventor
Donald J Abraham
Mona Mahran
Ahmed Mehanna
Ramnarayan Randad
Original Assignee
Univ Virginia Commonwealth
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from US07/702,947 external-priority patent/US5122539A/en
Application filed by Univ Virginia Commonwealth filed Critical Univ Virginia Commonwealth
Application granted granted Critical
Publication of ATE265208T1 publication Critical patent/ATE265208T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44—Iso-indoles; Hydrogenated iso-indoles
    • C07D209/48—Iso-indoles; Hydrogenated iso-indoles with oxygen atoms in positions 1 and 3, e.g. phthalimide
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/192—Carboxylic acids, e.g. valproic acid having aromatic groups, e.g. sulindac, 2-aryl-propionic acids, ethacrynic acid 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/195—Carboxylic acids, e.g. valproic acid having an amino group
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
    • A61K31/215—Esters, e.g. nitroglycerine, selenocyanates of carboxylic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/325—Carbamic acids; Thiocarbamic acids; Anhydrides or salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/01—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms
    • C07C233/16—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/24—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring
    • C07C233/29—Carboxylic acid amides having carbon atoms of carboxamide groups bound to hydrogen atoms or to acyclic carbon atoms having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by a carbon atom of a six-membered aromatic ring having the carbon atom of the carboxamide group bound to an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C233/00—Carboxylic acid amides
    • C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
    • C07C233/67—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms
    • C07C233/68—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
    • C07C233/73—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by singly-bound oxygen atoms with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom of a carbon skeleton containing six-membered aromatic rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C235/00—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms
    • C07C235/02—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton
    • C07C235/32—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings
    • C07C235/38—Carboxylic acid amides, the carbon skeleton of the acid part being further substituted by oxygen atoms having carbon atoms of carboxamide groups bound to acyclic carbon atoms and singly-bound oxygen atoms bound to the same carbon skeleton the carbon skeleton containing six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C271/00—Derivatives of carbamic acids, i.e. compounds containing any of the groups, the nitrogen atom not being part of nitro or nitroso groups
    • C07C271/06—Esters of carbamic acids
    • C07C271/40—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings
    • C07C271/58—Esters of carbamic acids having oxygen atoms of carbamate groups bound to carbon atoms of six-membered aromatic rings with the nitrogen atom of at least one of the carbamate groups bound to a carbon atom of a six-membered aromatic ring
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2602/00—Systems containing two condensed rings
    • C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
    • C07C2602/04—One of the condensed rings being a six-membered aromatic ring
    • C07C2602/08—One of the condensed rings being a six-membered aromatic ring the other ring being five-membered, e.g. indane
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C2603/00—Systems containing at least three condensed rings
    • C07C2603/56—Ring systems containing bridged rings
    • C07C2603/58—Ring systems containing bridged rings containing three rings
    • C07C2603/70—Ring systems containing bridged rings containing three rings containing only six-membered rings
    • C07C2603/74—Adamantanes

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Epidemiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Cardiology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Emergency Medicine (AREA)
  • Biomedical Technology (AREA)
  • Dermatology (AREA)
  • Diabetes (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Vascular Medicine (AREA)
  • Urology & Nephrology (AREA)
  • Hematology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
AT92912561T 1991-05-20 1992-05-19 Verwendung von allosterischen hämoglobinmodifikatoren zur verringerung der sauerstoffaffinität im blut ATE265208T1 (de)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US07/702,947 US5122539A (en) 1990-02-12 1991-05-20 Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood
US07/885,721 US5248785A (en) 1990-02-12 1992-05-18 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood
PCT/US1992/004229 WO1992020335A1 (en) 1991-05-20 1992-05-19 Using allosteric hemoglobin modifiers to decrease oxygen affinity in blood

Publications (1)

Publication Number Publication Date
ATE265208T1 true ATE265208T1 (de) 2004-05-15

Family

ID=27107045

Family Applications (2)

Application Number Title Priority Date Filing Date
AT02012781T ATE260886T1 (de) 1991-05-20 1992-05-19 Verwendung allosterischer hämoglobinmodifikatoren zur verringerung der sauerstoffaktivität im blut
AT92912561T ATE265208T1 (de) 1991-05-20 1992-05-19 Verwendung von allosterischen hämoglobinmodifikatoren zur verringerung der sauerstoffaffinität im blut

Family Applications Before (1)

Application Number Title Priority Date Filing Date
AT02012781T ATE260886T1 (de) 1991-05-20 1992-05-19 Verwendung allosterischer hämoglobinmodifikatoren zur verringerung der sauerstoffaktivität im blut

Country Status (9)

Country Link
US (1) US5248785A (de)
EP (3) EP1236711B1 (de)
JP (1) JP3023423B2 (de)
AT (2) ATE260886T1 (de)
CA (1) CA2109575C (de)
DE (2) DE69233320D1 (de)
DK (2) DK1236711T3 (de)
ES (2) ES2220857T3 (de)
WO (1) WO1992020335A1 (de)

Families Citing this family (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5432191A (en) * 1990-02-12 1995-07-11 The Center For Innovative Technology Allosteric hemoglobin modifiers to decrease oxygen affinity in blood
US5677330A (en) * 1990-02-12 1997-10-14 The Center For Innovative Technology Medical uses of allosteric hemoglobin modifier compounds in patient care
US5705521A (en) * 1990-02-12 1998-01-06 The Center For Innovative Technology Use of allosteric hemoglobin modifiers in combination with radiation therapy to treat carcinogenic tumors
US6458762B1 (en) 1994-03-28 2002-10-01 Baxter International, Inc. Therapeutic use of hemoglobin for preserving tissue viability and reducing restenosis
EP0767675A4 (de) * 1995-04-10 1998-08-05 Baxter Int Verwendung von vernetztem hämoglobin zur behandlung von subarachnoidalblutungen
US5733869A (en) * 1995-10-06 1998-03-31 Baxter International, Inc. Therapeutic administration of hemoglobin in cardiac arrest
AU2657597A (en) * 1996-03-21 1997-10-10 Dana-Farber Cancer Institute Use of allosteric haemoglobin modifier for treating solid tumors and inhibiting tumor metastases
JP2002501887A (ja) * 1998-01-28 2002-01-22 ワーナー−ランバート・カンパニー アルツハイマー病の治療方法
JP2003529543A (ja) * 1999-08-24 2003-10-07 ヴァージニア コモンウェルス ユニバーシティ 置換キラル・アロステリック・ヘモグロビン調節剤
EP1223942A2 (de) * 1999-08-25 2002-07-24 GMP Companies, Inc. Mittel zur verstärkten sauerstoffzufuhr bei säugern
DE10031741A1 (de) * 2000-06-29 2002-01-17 Sanguibio Tech Ag Einen Sauerstoffträger, ausgewählt aus Hämoglobin oder Hämoglobin- und Myoglobin-enthaltende Zubereitung als Externum zur natürlichen Regeneration der Haut bei Sauerstoff-Mangel
AU2002222552A1 (en) * 2000-11-29 2002-06-11 Kyorin Pharmaceutical Co. Ltd. Substituted carboxylic acid derivatives
US7097825B2 (en) * 2001-02-23 2006-08-29 Allos Therapeutics, Inc. Methods and reagents to acquire MRI signals and images
US20030232887A1 (en) * 2002-04-10 2003-12-18 Johnson Douglas Giles Preparation and use of a stable formulation of allosteric effector compounds
WO2003099153A1 (en) * 2002-05-21 2003-12-04 Allos Therapeutics, Inc. Device for using patient blood or blood fractions as diluent in administering pharmaceuticals
JP2007534691A (ja) * 2004-04-22 2007-11-29 アロス・セラピューティクス・インコーポレーテッド アロステリックヘモグロビン修飾体の組成物および前記組成物の製造法
US20070259966A1 (en) * 2004-04-22 2007-11-08 Allos Therapeutics, Inc. Coadministration of Radiation, Efaproxiral Sodium, and Supplemental Oxygen for the Treatment of Cancer
JP2007534683A (ja) * 2004-04-22 2007-11-29 アロス・セラピューティクス・インコーポレーテッド 癌の治療のための放射線、エファプロキシラルナトリウム、及び酸素補給の併用
EP1765760A1 (de) * 2004-07-01 2007-03-28 F.Hoffmann-La Roche Ag Eine acetylengruppe enthaltende phenylderivate
WO2007123126A1 (ja) * 2006-04-17 2007-11-01 Juridical Foundation Osaka Industrial Promotion Organization 慢性心不全における運動耐容能低下の改善剤
BRPI0705396B1 (pt) * 2007-12-12 2021-10-05 Universidade Estadual De Campinas - Unicamp Compostos derivados ftalimídicos
WO2015100235A1 (en) 2013-12-27 2015-07-02 Virginia Commonwealth University Allosteric hemoglobin modifiers with nitric oxide releasing moiety

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE2149070C3 (de) * 1971-10-01 1978-03-23 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäurederivate und deren Salze, Verfahren zu deren Herstellung und Arzneimittel
DE2432560A1 (de) * 1974-07-06 1976-01-22 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeurederivate und verfahren zur herstellung derselben
DE2541342A1 (de) * 1975-09-17 1977-03-31 Boehringer Mannheim Gmbh Neue phenoxyalkylcarbonsaeuren und verfahren zur herstellung derselben
DE2546996C2 (de) * 1975-10-21 1984-07-05 Boehringer Mannheim Gmbh, 6800 Mannheim Phenoxyalkylcarbonsäure-Derivate, Verfahren zur Herstellung derselben sowie Arzneimittel, die diese Verbindungen als Wirkstoff enthalten
US4704402A (en) * 1982-06-12 1987-11-03 University Of Pittsburgh Method of treating sickle cell anemia
US4887995A (en) * 1985-01-22 1989-12-19 University Of Pittsburgh Method of treating sickle cell anemia
US4699926A (en) * 1986-04-04 1987-10-13 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4751244A (en) * 1986-04-04 1988-06-14 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US4731381A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Method of treating a person for sickle cell anemia
US4731473A (en) * 1986-04-04 1988-03-15 Merck & Co., Inc. Compounds useful in treating sickle cell anemia
US5049695A (en) * 1990-02-12 1991-09-17 Center For Innovative Technology Allosteric hemoglobin modifiers
US5122539A (en) * 1990-02-12 1992-06-16 Center For Innovative Technology Allosteric hemoglobin modifiers useful for decreasing oxygen affinity and preserving oxygen carrying capability of stored blood

Also Published As

Publication number Publication date
DE69233348T2 (de) 2005-05-12
JPH07508973A (ja) 1995-10-05
DE69233320D1 (de) 2004-04-08
EP0585366B1 (de) 2004-04-28
EP0585366A4 (de) 1994-03-17
WO1992020335A1 (en) 1992-11-26
CA2109575A1 (en) 1992-11-26
EP0585366A1 (de) 1994-03-09
EP1468680A3 (de) 2005-04-13
ES2223042T3 (es) 2005-02-16
DK0585366T3 (da) 2004-08-09
DE69233348D1 (de) 2004-06-03
EP1468680A2 (de) 2004-10-20
CA2109575C (en) 2000-02-01
JP3023423B2 (ja) 2000-03-21
DK1236711T3 (da) 2004-08-16
US5248785A (en) 1993-09-28
ES2220857T3 (es) 2004-12-16
EP1236711A3 (de) 2002-09-18
EP1236711B1 (de) 2004-03-03
ATE260886T1 (de) 2004-03-15
EP1236711A2 (de) 2002-09-04

Similar Documents

Publication Publication Date Title
ATE265208T1 (de) Verwendung von allosterischen hämoglobinmodifikatoren zur verringerung der sauerstoffaffinität im blut
ATE117805T1 (de) Stabile hämoglobinreferenzlösung.
ATE203913T1 (de) Eine gelpräparation aus vernetzter gelatine, die einen basischen wachstumsfaktor für fibroblasten enthält
ATE108186T1 (de) Kontrollierte oxydation von mikrobiell hergestellten cysteine enthaltenden proteinen.
DE3851225D1 (de) Blutersatz.
ES8603271A1 (es) Un metodo de producir una composicion de interleuquina-2
DK138590D0 (da) Middel til transdermal applikation indeholdende gestoden
NO892303D0 (no) Stabilisert fgf-sammensetning og fremstilling derav.
NO894337D0 (no) Hydrolyserte kopolymerer av n-vinylamid og akrylamid for bruk som vanntapsregulerende additiver i boreslam.
PT871476E (pt) Composicao seca de factor sanguineo compreendendo trealose
GR3015295T3 (en) Low volatility salts.
ES2087162T3 (es) Tratamiento de la diabetes insulino-resistente.
ES2041977T3 (es) Impplante percutaneo.
EP0354185A3 (de) Piperidin-Triazin-Verbindungen und ihre Verwendung als Stabilisatoren für organische Materialien
NO931956D0 (no) Imidoesterkryssbundne hemoglobinpreparater
DE69002697D1 (de) Carboplatinzusammensetzung.
KE3282A (en) Hair treatment composition and method
ATE95421T1 (de) Piroxicam enthaltende pharmazeutische zusammensetzung zur topischen anwendung.
DE59408956D1 (de) Verwendung von Hydroxyethylstärke zur Verbesserung der Mikrozirkulation
DE69633918D1 (de) Mutantes hämoglobin mit niedriger affinität für sauerstoff
SE8602904D0 (sv) Forfarande for stabilisering av enzymet laktoperoxidas i produkter
EP0351017A3 (en) Pharmaceutical composition useful for the treatment of cardiovascular diseases
DE68913797D1 (de) Verwendung von Paraaminosalicylsäure zur Stabilisierung der enzymatischen Aktivität von Peroxydase in Lösung, Stabilisierungsmittel und Verwendung von stabiliserter Lösung.
UA13666A1 (uk) Спосіб визhачеhhя стійкості еритроцитів до гемолізу
EP0261802A3 (de) Perfluoro-hexamethyltetramin und synthetische Phopholipide, verwendbar als synthetisches Blut

Legal Events

Date Code Title Description
UEP Publication of translation of european patent specification

Ref document number: 0585366

Country of ref document: EP

REN Ceased due to non-payment of the annual fee